French To Launch Two-Year Medicinal Cannabis Pilot Project
A two-year pilot program in France will look at the practicalities of prescribing medicinal cannabis for patients with one of five specific conditions.
You may also be interested in...
New draft guidance from the health technology assessment body NICE says that more evidence is needed on cannabis-based medicines before they can be more widely used. In the meantime, it says they should not be used in chronic pain, epilepsy or spasticity in multiple sclerosis, while nabilone may be used for chemotherapy-related sickness.
A new regulatory scheme for medicinal cannabis products, complete with a brand new agency, is on the cards in New Zealand, based on a strict licensing and quality control system that is intended to increase the supply of, and patient access to, such products.
The pharmaceutical industry has come under attack by a UK parliament committee for failing to make medicinal cannabis products available for clinical trials, saying that a "robust research base" is needed on which to base future treatment decisions.